Bivalirudin: In patients with acute coronary syndromes planned for urgent or early intervention

Drugs

Volumn 68, Issue 16, 2008, Pages 2345-2356

  Deeks, Emma D ^a,b   Curran, Monique P ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Acute coronary syndromes; Adis Drug Profiles; Bivalirudin, general

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEMOGLOBIN; HEPARIN; HIRULOG; TICLOPIDINE; TROPONIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DISEASE; LOADING DRUG DOSE; LONG TERM CARE; MONOTHERAPY; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; RETROPERITONEAL HEMORRHAGE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSPECIFIED SIDE EFFECT;

ANGINA;

EID: 55049131196     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868160-00006     Document Type: Review

References (40)

1. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007 Jul; 28 (13): 1598-660
2. Wiggins BS, Spinler S. Antiplatelet and antithrombin therapy for early management of acute coronary syndromes. J Pharmacy Practice 2004; 17 (5): 347-69
3. American Heart Association and American Stroke Association. Heart disease and stroke statistics: 2008 update at-a-glance [online]. Available from URL: http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008. final.pdf [Accessed 2008 Jun 3]
4. Ramanath VS, Eagle KA. Evidence-based medical therapy of patients with acute coronary syndromes. Am J Cardiovasc Drugs 2007; 7 (2): 95-116
5. Mehta SR, Cannon CP, Fox KAA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005 Jun 15; 293 (23): 2908-17
6. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007 Aug 14; 50 (7): e1-157
7. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003 Oct; 24 (20): 1815-23
8. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004 Oct 6; 292 (13): 1555-62
9. Segev A, Strauss BH, Tan M, et al. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005 Oct; 150 (4): 690-4
10. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004 Mar; 17 (1): 105-25
11. European Medicines Agency. Angiox: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ angiox/H-562-PI-en.pdf [Accessed 2008 May 14]
12. US Food and Drug Administration. Angiomax®: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/ 2005/020873s011lbl.pdf [Accessed 2008 Jun 20]
13. Moen MD, Keating GM, Wellington K. Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention. Drugs 2005; 65 (13): 1869-91
14. Carswell CI, Plosker GL. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 2002; 62 (5): 841-70
15. Bates ER. Bivalirudin: an anticoagulant option for percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2004 Mar; 2 (2): 153-62
16. Nielsen VG, Steenwyk BL, Gurley WQ, et al. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 2006 Jun; 25 (6): 653-63
17. Tanaka KA, Szlam F, Sun HY, et al. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg 2007 Oct; 105 (4): 933-9
18. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993 Feb 1; 69 (2): 157-63
19. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004 May 1; 93 (9): 1092-6
20. Robson R, White H, Aylward P, et al. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002 Jun; 71 (6): 433-9
21. Kleiman NS, Klem J, Fernandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002 Apr; 143 (4): 585-93
22. Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993 Apr 1; 71 (10): 778-82
23. Lidón R-M, Théroux P, Juneau M, et al. Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation 1993 Oct; 88 (4 Pt 1): 1495-501
24. Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007 Aug 1; 100 (3): 417-24
25. Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 2002 Jun; 13 (3): 161-5
26. Keating FK, Dauerman HL, Whitaker DA, et al. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118 (3): 361-9
27. Lev EI, Patel R, Karim A, et al. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. Thromb Haemost 2006 Mar; 95 (3): 441-6
28. Keating FK, Dauerman HL, Whitaker DA, et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005 Sep 1; 16 (6): 401-5
29. Irvin W, Sica D, Gehr T, et al. Pharmacodynamics (PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD) [abstract no. PIII-104]. Clin Pharmacol Ther 1999 Feb; 65 (2): 202
30. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995 Aug 15; 92 (4): 727-33
31. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. Am Heart J 2002 Feb; 143 (2): 229-34
32. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 Nov 23; 355 (21): 2203-16
33. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007 Dec 5; 298 (21): 2497-506
34. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Lancet 2007 Mar 17; 369 (9565): 907-19
35. White HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008 May 6; 51 (18): 1734-41
36. Feit F, Manoukian SV, Ebrahimi R, et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008 Apr 29; 51 (17): 1645-52
37. White HD, Ohman M, Lincoff AM, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008 Sep 2; 52 (10): 807-14
38. European Medicines Agency. Angiox: scientific discussion [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/angiox/ Angiox-AR-H-562-II-08.pdf [Accessed 2008 Jul 25]
39. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 2004 Nov; 148 (5): 764-75
40. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000 Aug 16; 284 (7): 835-42